Background The study aimed to examine the significance of insulin receptor (INSR)
expression in predicting resistance to axitinib in clear cell renal cell carcinoma (ccRCC) …

Purpose This study aimed to clarify the molecular mechanism mediating the cytotoxicity of
axitinib, a selective inhibitor of the vascular endothelial growth factor receptor (VEGFR), in …

Abstract Objectives To conduct Japanese subgroup analyses of a randomized, global Phase
II study of axitinib with and without dose titration in first-line metastatic renal cell carcinoma …

Aim: To investigate prognostic factors for patients with advanced renal cell carcinoma (RCC)
treated with axitinib as second-line therapy. Patients and Methods: This study included 35 …

The multikinase inhibitors sunitinib, sorafenib, and axitinib have an impact not only on tumor
growth and angiogenesis, but also on the activity and function of immune effector cells. In …

Background Axitinib has shown activity in metastatic renal cell carcinoma (mRCC) in a large
phase III clinical trial and was approved in patients who failed first-line therapy. This drug …

Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer.
Despite the availability of several tyrosine kinase inhibitors (TKI) and immunotherapies in …

Background A prospective, randomised phase II study demonstrated clinical benefit of
axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for …

Objective Axitinib is an oral multi-target tyrosine kinase inhibitor used for the treatment of
renal cell carcinoma (RCC). Because of the severe adverse events (AEs) associated with …

Background To investigate the impact of proteinuria on the renal function of patients with
metastatic renal cell carcinoma (mRCC) who received axitinib, a tyrosine kinase inhibitor …